Medical use of a DPP-4 inhibitor
First Claim
Patent Images
1. A method for treating a patient being at risk of or having heart failure with preserved ejection fraction (HFpEF), the method comprising administering to the patient 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine, optionally in combination with one or more other active agents.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to the use of 1-[(4-methyl-quinazolin-2-yl)methyl]-3 -methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine for use in a patient being at risk of or having heart failure with preserved ejection fraction (HFpEF).
-
Citations
8 Claims
- 1. A method for treating a patient being at risk of or having heart failure with preserved ejection fraction (HFpEF), the method comprising administering to the patient 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine, optionally in combination with one or more other active agents.
Specification